Latham & Watkins Advises Odyssey on Sale of Mercalis

Odyssey Investment Partners has announced that it has entered into a definitive agreement to sell Mercalis Inc., a leading provider of life sciences and pharmaceutical commercialization services, to PharmaCord LLC, a portfolio company of Permira, in a merger to create one of the largest independent total solutions providers to the biopharmaceutical industry. Financial terms of the transaction were not disclosed. The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions. 

Latham & Watkins represents Odyssey Investment Partners in the transaction with a corporate deal team led by New York partners Paul Kukish, Michael Vardanian, and Daniel Williams, with associates Josh Meyer, Kathryn Sarkesian, and Emilie Cullen. Advice was also provided on tax matters by New York partner Jocelyn Noll, with associate James Aldred; on healthcare regulatory matters by Bay Area partner Betty Pang, with associate Yanyan Zhou; on benefits and compensation matters by New York partners Bradd Williamson and Megan Alessi, with associates Anne Bracaglia and Seokwon Lee; on labor and employment matters by Chicago counsel Laura Waller, with associate Jocelyn Wexler; on intellectual property matters by New York partner Jeffrey Tochner, with associate Sebastian Moss; on data privacy matters by Bay Area partner Robert Blamires, with associates Kiara Vaughn and Zac Alpert; on finance matters by New York partner Joshua Tinkelman, with associates Melissa Doura and Kavi Huded; on environmental matters by New York counsel David Langer, with associate Brittany Curcuru; on real estate matters by New York counsel Lisa Brabant, with associate Chika Onyejiukwa; and on antitrust matters by Washington, D.C. partners Jason Cruise and Patrick English, with associates Andrew Paik and Ben Bouwman.